6533b839fe1ef96bd12a6639
RESEARCH PRODUCT
Successful treatment of life-threatening bleeding after cesarean section with recombinant activated factor VII.
L HeilmannB. HojnackiKunhard PollowC. Wildsubject
Adultmedicine.medical_specialtyPacked Red CellsCritical IllnessUterotonicFactor VIIa030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicinelawPregnancyActivated factor VIImedicineCoagulopathyHumans030212 general & internal medicinepostpartum bleedingbusiness.industryCesarean SectionPostpartum HemorrhageUterine bleedingHematologyGeneral MedicineFactor VIImedicine.diseaseRecombinant ProteinsSurgeryTreatment OutcomeAnesthesiaHemorrhagic shockRecombinant DNAFemalebusinessdescription
Hemorrhagic shock developed in a 29-year-old nullipara without coagulopathy after emergency caesarean section. Treatment with uterotonic drugs, prostaglandins, and conservative procedures with transfusion of packed red cells and fresh-frozen plasma failed to control the diffuse vaginal and uterine bleeding. Finally an intravenous bolus injection of 90 μg/kg recombinant activated factor VII (rFVIIa, NovoSeven®, Novo Nordisk A/S, Bagsvaerd, Denmark), was given and showed success within 20 minutes after administration, without any side effects.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2006-05-19 | Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis |